What's hot

View all perspectives
What's Hot
Sleep asleep

Sleep Quality & Psoriatic Arthritis

For people living with psoriatic arthritis (PsA), the comfort of a good night's sleep may feel out of reach for many.

Read more →

Ultrasound in PsA

Dr. Arthur Kavanaugh discusses abstract 2206 presented at ACR22 in Philadelphia. Abstract 2206: Understanding Inter-rater Variability in Scoring of Entheseal Lesions: Results from the Diagnostic Ultrasound Enthesitis Tool (DUET) Study

Watch video →

Tapering TNFi in nonradiographic AxSpA

Dr. Peter Nash at ACR22 Convergence in Philadelphia, PA.

Watch video →

Sunday (Day 2): ACR 22 Daily Recap

ACR 2022 Daily Recap for Sunday, November 13th. Panelists: Drs. Robert Chao, Antoni Chan, Bella Mehta, Janet Pope, Yuz Yusof, Cassy Sims, Akhil Sood, Sheila Reyes and Jack Cush.

Watch video →

Spondyloarthritis: Novel Therapies, Diagnostic Dilemmas and Depression

Dr. Lianne Gensler discusses the following abstracts presented at ACR22 Convergence. Abstracts 1597, 1598, 1599 (treatment) and 1613, 1609 and 1614 (diagnosis and outcomes)

Watch video →

Deucravacitinib in PsA

Dr. Arthur Kavanaugh discusses abstract 1598 at ACR22 Convergence in Philadelphia. Abstract 1598: Safety and Efficacy of Deucravacitinib, an Oral, Selective Tyrosine Kinase 2 Inhibitor, in Patients with Psoriatic Arthritis: 52-Week Results from a Randomized Phase 2 Trial

Watch video →

Sarilumab in Polymyalgia Rheumatica: Results from SAPHYR Trial

Dr. Michael Putman interviews Dr. Robert Speira about abstract 1676 presented at the ACR22 Convergence meeting in Philadelphia, PA. Abstract 1676: Sarilumab in Patients with Relapsing Polymyalgia Rheumatica: A Phase 3, Multicenter, Randomized, Double Blind, Placebo Controlled Trial (SAPHYR)

Watch video →

Best of ACR Day Two in PSA

Watch video →

PET CT Imaging to Define Risk of Progression from PSO to PsA

Dr. Peter Nash discusses Abstract 1018 at ACR22 Convergence.

Watch video →

ACR22 Daily Recap: Saturday Recap

Panelists: Drs. Jack Cush, Michael Putman, Eric Dein, Patricia Harkins and Rachel Tate. 

Watch video →
      RT @DrCassySims: 🔥Ignite Talk 10:20AM South Philly Stage🔥 abstract #0946

      SLE, birth control, & pregnancy pla

      Catherine Sims, MD DrCassySims

      3 years 1 month ago
      🔥Ignite Talk 10:20AM South Philly Stage🔥 abstract #0946 SLE, birth control, & pregnancy planning 🔥30% of women used no birth control despite only 17% voicing interest in pregnancy 🔥More 1/2 of women interested in pregnancy were not medically ready #ACR22 @RheumNow
      RT @RichardPAConway: Vilas-Boas et al. Anti-NOR antibodies. 27.5% of anti-NOR+ diagnosed with rheumatic disease - SSc an

      Richard Conway RichardPAConway

      3 years 1 month ago
      Vilas-Boas et al. Anti-NOR antibodies. 27.5% of anti-NOR+ diagnosed with rheumatic disease - SSc and UCTD most common. @RheumNow #ACR22 Abstr#0832 https://t.co/OU2hFn3ioK https://t.co/Ve0Jbexycm
      RT @RichardPAConway: Kahlenberg @Kahlenberglab et al. TYK2i deucravacitinib in SLE. Clinical efficacy (figure). Deucrava

      Richard Conway RichardPAConway

      3 years 1 month ago
      Kahlenberg @Kahlenberglab et al. TYK2i deucravacitinib in SLE. Clinical efficacy (figure). Deucravacitinib suppressed IFN production, IFN-responsive gene expression, IFN-inducible proteins, B cell markers,serological biomarkers. @RheumNow #ACR22 Abstr#1000 https://t.co/zzkoPLOlSR https://t.co/znyG8N5pJ2
      RT @RichardPAConway: Johnson et al TYK2i deucravacitinib does not inhibit haematologic pathways, Treg function, or IL-15

      Richard Conway RichardPAConway

      3 years 1 month ago
      Johnson et al TYK2i deucravacitinib does not inhibit haematologic pathways, Treg function, or IL-15 dependent NK cell function, that JAKi do. @rheumnow #ACR22 Abstr#0584 https://t.co/UTHzUjGmJN https://t.co/NUKKAv3tAr
      RT @uptoTate: Severe non-adherence to HCQ independently assoc'd w/ risk of SLE flare in the following year, with early d

      Dr. Rachel Tate uptoTate

      3 years 1 month ago
      Severe non-adherence to HCQ independently assoc'd w/ risk of SLE flare in the following year, with early damage, and 5-year mortality. Abs 0343 #ACR22 @RheumNow https://t.co/JYRWD5QIlf https://t.co/UCWYrHIc4b
      RT @RichardPAConway: Gopal et al. Withdrawal of immunosuppressants non-inferior to steroid withdrawal in SLE in clinical

      Richard Conway RichardPAConway

      3 years 1 month ago
      Gopal et al. Withdrawal of immunosuppressants non-inferior to steroid withdrawal in SLE in clinical remission. Numerically higher flare rate in steroid withdrawal group 15 vs 7 (RR 2.1). @RheumNow #ACR22 Abstr#0997 https://t.co/psoHvg0pVG https://t.co/GlsDjpgXGo
      RT @RichardPAConway: Giblon et al. Incidence depression and anxiety in RA over 30 years. No change in depression, signif

      Richard Conway RichardPAConway

      3 years 1 month ago
      Giblon et al. Incidence depression and anxiety in RA over 30 years. No change in depression, significant increase in anxiety @RheumNow #ACR22 Abstr#0886 https://t.co/1a3sayBEnl https://t.co/jflc3UTbIh
      RT @RichardPAConway: Bui et al. Outcomes in Adult onset Stills Disease. >40% required ICU admission and 3.5% died in

      Richard Conway RichardPAConway

      3 years 1 month ago
      Bui et al. Outcomes in Adult onset Stills Disease. >40% required ICU admission and 3.5% died in this retrospective study. No effect of concomittent pneumonia. @RheumNow #ACR22 Abstr#0829 https://t.co/YxkXJJ7EGR https://t.co/mMbQ14iRL1
      RT @RichardPAConway: Madan et al. Ferritin levels more than 7511 and ferritin/ CRP levels more than 204.5 was associated

      Richard Conway RichardPAConway

      3 years 1 month ago
      Madan et al. Ferritin levels more than 7511 and ferritin/ CRP levels more than 204.5 was associated with higher mortality in Macrophage Activation Syndrome @RheumNow #ACR22 Abstr#0825 https://t.co/jL58oCCEWa https://t.co/9V4PW49EyC
      RT @RichardPAConway: Ma et al. Calprotectin differentiates remission and low disease activity in RA. @RheumNow #ACR22 Ab

      Richard Conway RichardPAConway

      3 years 1 month ago
      Ma et al. Calprotectin differentiates remission and low disease activity in RA. @RheumNow #ACR22 Abstr#0884 https://t.co/z9oeKPLq5z https://t.co/YFkIBEqT0c
      RT @DrTrishHarkins: Sarilumab in GC resistant PMR
      🔥SAPHYR🔥

      👉Arm 1- sar 200mg Q2W + 14wk GC
      👉

      Patricia Harkins DrTrishHarkins

      3 years 1 month ago
      Sarilumab in GC resistant PMR 🔥SAPHYR🔥 👉Arm 1- sar 200mg Q2W + 14wk GC 👉 Arm 2- PBO Q2W + 52wk GC 🌟RESULTS🌟 💪🏻 Arm 1 - PMR symp + signs ⬇️ wk 2 with continued improvement until wk 52 🌟Arm 1- ⬇️ chance flare post achieving remission #ACR22 @RheumNow https://t.co/tXQuuoAelP
      RT @uptoTate: CLE to SLE transition occurred more frequently in pts aged 40 and younger, w/in the first 10 years of dx,

      Dr. Rachel Tate uptoTate

      3 years 1 month ago
      CLE to SLE transition occurred more frequently in pts aged 40 and younger, w/in the first 10 years of dx, and those with SCLE. Abs 0338 #ACR22 @RheumNow https://t.co/XxHjkNL5Hf https://t.co/1WtgmVM7Iz
      RT @RichardPAConway: Saxena et al Zetomipzomib, a selective immunoproteasome inhibitor in lupus nephritis. Phase 2 study

      Richard Conway RichardPAConway

      3 years 1 month ago
      Saxena et al Zetomipzomib, a selective immunoproteasome inhibitor in lupus nephritis. Phase 2 study. UPCR=<0.5 achieved 64.7% week 37, pred=<10mg/day 82.4% week 13. @RheumNow #ACR22 Abstr#0992 https://t.co/askpmqsYYG https://t.co/cKoR0bgtWt
      RT @RichardPAConway: Wallace @zach_wallace_md et al. IgG4-RD in USA. Incidence 1.2/100,000, prevalence 2.8/100,000. Panc

      Richard Conway RichardPAConway

      3 years 1 month ago
      Wallace @zach_wallace_md et al. IgG4-RD in USA. Incidence 1.2/100,000, prevalence 2.8/100,000. Pancreas (43.0%), biliary tract (30.6%), salivary glands (11.7%), retroperitoneum (5.0%). HR 2.51 for mortality in IgG4-RD. @RheumNow #ACR22 Abstr#0713 https://t.co/IpjSKxmHQN
      RT @DrCassySims: Opioid use in adults with PsA and AS

      Abstract #0402 @RheumNow #ACR22

      ✋828 PsA patients ➡️ 21%

      Catherine Sims, MD DrCassySims

      3 years 1 month ago
      Opioid use in adults with PsA and AS Abstract #0402 @RheumNow #ACR22 ✋828 PsA patients ➡️ 21% used opioids 🦴 334 AS patients ➡️ 27% used opioids 💊Opioid users had more comorbidities, more medical visits, worse disease activity, and higher prevalence of 🚬

      Podcasts

      • ACR2022 - Day 4 00:14:40
      • Monday ACR 2022 Daily Recap 00:37:20
      • ACR2022 - Day 3.3 00:34:23

      Catch up on Conference Podcasts

      ×